Stem Cells as a symptom- and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis: a randomised placebo-controlled trial
Latest Information Update: 24 Nov 2020
At a glance
- Drugs CYP 004 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SCUlpTOR
Most Recent Events
- 11 Nov 2020 According to a Cynata Therapeutics media release, subject treatment will commence with an initial four patients from the University's volunteers database, who will be assessed for four weeks, before the study opens for enrolment more widely. As no additional volunteers are being sought at this time, patients who are interested in participating in the trial should wait until wider enrolment commences before contacting study centres, which is expected to happen early in 2021.
- 11 Nov 2020 Status changed from planning to recruiting, according to a Cynata Therapeutics media release.
- 18 Jun 2020 According to a Cynata Therapeutics media release, it is funded by an Australian Government NHMRC Project Grant, in addition to in-kind contributions from participating institutions. Cynata will supply Cymerus™ MSCs for use in the trial and will not be required to contribute any cash to fund the project